Free Trial
NASDAQ:AMRS

Amyris (AMRS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.05
$1.17
52-Week Range
N/A
Volume
46.75 million shs
Average Volume
12.59 million shs
Market Capitalization
$18.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AMRS stock logo

About Amyris Stock (NASDAQ:AMRS)

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

AMRS Stock News Headlines

Amyris Receives Court Approval for Restructuring Plan
Bigger Than NVIDIA?
With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.
Bigger Than NVIDIA?
With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.
Amyris Inc AMRSQ
Gevo's Valentine's Day Massacre
Amyris, Inc. (AMRS) Soars: Stock Up 16.0%
Firm Retention Summary: Amyris
Why Amyris Stock Is Rocketing Higher
AMRS Stock Surges 152% as Amyris Files for Bankruptcy
See More Headlines
Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
6/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Specialty Chemicals
Sub-Industry
Oil & Gas Refining & Marketing
Current Symbol
NASDAQ:AMRS
CUSIP
03236M10
Employees
1,598
Year Founded
2003

Profitability

Net Income
$-528,510,000.00
Net Margins
-229.12%
Pretax Margin
-235.25%

Debt

Sales & Book Value

Annual Sales
$269.85 million
Book Value
($1.52) per share

Miscellaneous

Free Float
235,299,000
Market Cap
$18.47 million
Optionable
Optionable
Beta
1.19

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


AMRS Stock Analysis - Frequently Asked Questions

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company earned $47.90 million during the quarter, compared to analysts' expectations of $64.21 million. The company's quarterly revenue was up 39.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.41) earnings per share.

What ETF holds Amyris' stock?

AXS Cannabis ETF holds 467,857 shares of AMRS stock, representing 3.26% of its portfolio.

When did Amyris' stock split?

Amyris's stock reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is John Melo's approval rating as Amyris' CEO?

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

This page (NASDAQ:AMRS) was last updated on 6/18/2024 by MarketBeat.com Staff

From Our Partners